Becton Dickinson and Co (BDX) Expected to Announce Quarterly Sales of $4.44 Billion

Wall Street brokerages expect Becton Dickinson and Co (NYSE:BDX) to report $4.44 billion in sales for the current quarter, according to Zacks. Eight analysts have issued estimates for Becton Dickinson and’s earnings. The lowest sales estimate is $4.38 billion and the highest is $4.48 billion. Becton Dickinson and posted sales of $4.28 billion in the same quarter last year, which suggests a positive year over year growth rate of 3.7%. The firm is scheduled to announce its next quarterly earnings results on Thursday, August 1st.

On average, analysts expect that Becton Dickinson and will report full year sales of $17.42 billion for the current financial year, with estimates ranging from $17.32 billion to $17.49 billion. For the next year, analysts forecast that the firm will post sales of $18.33 billion, with estimates ranging from $18.19 billion to $18.52 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for Becton Dickinson and.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.57 by $0.02. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. The firm had revenue of $4.20 billion during the quarter, compared to analyst estimates of $4.25 billion. During the same quarter in the previous year, the company posted $2.65 earnings per share. The company’s revenue was down .6% compared to the same quarter last year.

Several equities research analysts have issued reports on the company. TheStreet raised Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday, February 5th. Piper Jaffray Companies lifted their price target on Becton Dickinson and to $274.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 5th. UBS Group dropped their price target on Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday. Wells Fargo & Co reaffirmed an “outperform” rating and set a $265.00 price target (down previously from $280.00) on shares of Becton Dickinson and in a research note on Monday. Finally, BMO Capital Markets dropped their price target on Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating for the company in a research note on Friday. Six investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $255.31.

In other news, EVP Ribo Alberto Mas sold 4,808 shares of Becton Dickinson and stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $255.03, for a total value of $1,226,184.24. Following the transaction, the executive vice president now owns 22,476 shares in the company, valued at $5,732,054.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Vincent A. Forlenza sold 11,340 shares of Becton Dickinson and stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $250.40, for a total value of $2,839,536.00. Following the completion of the transaction, the chief executive officer now owns 227,250 shares in the company, valued at approximately $56,903,400. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,684 shares of company stock worth $7,518,574. Company insiders own 0.12% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new position in Becton Dickinson and during the 3rd quarter valued at about $953,000. Vanguard Group Inc increased its holdings in Becton Dickinson and by 1.3% during the 3rd quarter. Vanguard Group Inc now owns 21,666,262 shares of the medical instruments supplier’s stock valued at $5,654,895,000 after purchasing an additional 283,433 shares during the period. Union Bankshares Corp increased its holdings in Becton Dickinson and by 7.5% during the 4th quarter. Union Bankshares Corp now owns 19,973 shares of the medical instruments supplier’s stock valued at $4,501,000 after purchasing an additional 1,401 shares during the period. Waverton Investment Management Ltd increased its holdings in Becton Dickinson and by 0.8% during the 4th quarter. Waverton Investment Management Ltd now owns 480,753 shares of the medical instruments supplier’s stock valued at $108,323,000 after purchasing an additional 3,680 shares during the period. Finally, Cozad Asset Management Inc. increased its holdings in Becton Dickinson and by 2.7% during the 4th quarter. Cozad Asset Management Inc. now owns 2,618 shares of the medical instruments supplier’s stock valued at $590,000 after purchasing an additional 68 shares during the period. Hedge funds and other institutional investors own 84.96% of the company’s stock.

Shares of BDX stock opened at $223.69 on Tuesday. The company has a debt-to-equity ratio of 0.82, a current ratio of 0.96 and a quick ratio of 0.62. Becton Dickinson and has a 12-month low of $208.62 and a 12-month high of $265.87. The stock has a market cap of $61.83 billion, a price-to-earnings ratio of 20.32, a PEG ratio of 1.67 and a beta of 1.16.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Friday, June 7th will be issued a $0.77 dividend. The ex-dividend date is Thursday, June 6th. This represents a $3.08 annualized dividend and a dividend yield of 1.38%. Becton Dickinson and’s dividend payout ratio is currently 27.97%.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: Is the QQQ ETF safe?

Get a free copy of the Zacks research report on Becton Dickinson and (BDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.